5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming

BACKGROUND: Epigenetic therapy through demethylation of 5-methylcytosine has been largely ineffective in treating lung cancer, most likely due to poor tissue distribution with oral or subcutaneous delivery of drugs such as 5-azacytidine (5AZA). An inhalable, stable dry powder formulation of 5AZA was...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Br J Cancer
Hauptverfasser: Kuehl, Philip J., Tellez, Carmen S., Grimes, Marcie J., March, Thomas H., Tessema, Mathewos, Revelli, David A., Mallis, Larry M., Dye, Wendy W., Sniegowski, Tyler, Badenoch, Aaron, Burke, Michael, Dubose, Devon, Vodak, David T., Picchi, Maria A., Belinsky, Steven A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group UK 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7156464/
https://ncbi.nlm.nih.gov/pubmed/32103148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0765-2
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge